News Careers Contact About Science Pipeline Patients Investors At eFFECTOR Therapeutics, these are the questions we are dedicated to answering. Who are the leaders paving a new way in oncology? Meet Our Team eFFECTOR is made up of industry veterans who have played crucial roles in drug discovery and development. But more importantly, we are a team that knows patients deserve more effective treatment options. And we believe these are within reach. What are selective translation regulator inhibitors? Dive Into Our Pipeline Cancer is a complex, aggressive disease driven by multiple factors that propel uncontrolled growth and enable it to evolve to evade existing therapies. We are pioneering a new class of cancer therapies called selective translational regulator inhibitors (STRIs) –designed to outsmart cancer’s complexity, create better outcomes for patients and block the production of many cancer-driving proteins simultaneously. Interested in joining a team that’s working to outsmart cancer? Explore Our Openings Outsmarting one of the most complex diseases is something that requires rigor, creativity and an unrelenting, dynamic outlook. These are the types of skillsets and mentalities you can expect to find at eFFECTOR Therapeutics. Interested in becoming a part of it? About Science Pipeline Patients Investors News Careers Contact Copyright © 2021 eFFECTOR Therapeutics, Inc. | Privacy Policy

Skip to main navigation News Careers Contact About Science Pipeline Patients Investors PRESS RELEASES Press Releases Events & Presentations Corporate Governance Financials & Filings Stock Information IR Resources Year 2021 eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology 11.24.2021 eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit 11.22.2021 eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update 11.08.2021 eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors 11.01.2021 eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences 10.26.2021 Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 10.07.2021 Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 09.30.2021 eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference 09.16.2021 eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies 08.25.2021 eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer 08.04.2021 Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17 Print Page Email Alerts RSS Feeds Search About Science Pipeline Patients Investors News Careers Contact Copyright © 2021 eFFECTOR Therapeutics, Inc. | Privacy Policy